Leading Czech Republic Research Institute Chooses Genedata for Data Analysis in Biomarker Project
Basel, Switzerland (PRWEB) October 19, 2009 -- Genedata, a leading provider of in silico solutions for pharmaceutical R&D and related life sciences, today announced a collaboration with the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, to study the effects of air pollution on asthma bronchiale in young children. Genedata will examine the study data and apply Genedata Expressionist® to process and analyze transcriptomics data in conjunction with genetic polymorphism and clinical data.
"We will take advantage of Genedata's expertise and their powerful software to process and analyze large amounts of toxicogenomics data, standardize the quality assessment process of the primary data and deliver reliable and robust data analysis results," explained Radim J. Sram, M.D., D.Sc., head of the Laboratory of Genetic Ecotoxicology at the Institute of Experimental Medicine, Academy of Sciences (Prague). "We chose Genedata after our previous successful collaboration studying genome-wide differential gene expression in children exposed to air pollution. Using Expressionist, researchers demonstrated how transcriptomic analysis can be effectively used as a promising biomarker detection method for the effect of environmental carcinogens."
The asthma bronchiale project focuses on investigating and understanding the effects of air pollution on gene expression and the individual genetic susceptibility to the effects of toxic air pollutants in selected children cohorts from various regions of the Czech Republic. The diagnosis of asthma bronchiale in children has increased from 10% in 2001 to 30% in 2007 in the Ostrava-Bartovice region. This alarming trend is now being investigated looking at dust particles containing carcinogenic polycyclic aromatic hydrocarbons (c-PAHs) as these particles are thought to contribute to the increase of asthma bronchitis. Inherited genetic factors are also being studied to provide further information to improve the mechanistic understanding of the causes of the disease.
"We are excited about the asthma bronchiale project and to contribute to uncovering the mechanism of action of the disease in children," noted Dr. Othmar Pfannes, CEO of Genedata. "This collaboration further demonstrates Genedata's commitment to biomarker research and providing statistical data analysis across multiple research groups and locations."
About The Institute of Experimental Medicine, Academy of Sciences of the Czech Republic
The Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, is the leading institution in the Czech Republic for biomedical research, particularly in cell biology and pathology, neurobiology, neurophysiology, neuropathology, developmental toxicology and teratology, molecular epidemiology, molecular pharmacology, immunopharmacology, molecular embryology, stem cells and nervous tissue regeneration. The Institute is an internationally recognized center in these fields, and as such it was selected as an EU Center of Excellence (MEDIPRA). For more information visit www.iem.cas.cz.
Genedata develops and globally markets sophisticated computational solutions for drug discovery and related research processes in the life sciences. Genedata's solutions enable scientists to process, integrate, analyze, and manage large and complex experimental data sets generated by high throughput technologies. Solutions include Genedata Phylosopher® for target discovery and integrative biological data management, Genedata Screener® for automated high throughput screening and high content screening, and Genedata Expressionist® for biomarker discovery and personalized medicine. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Boston & San Francisco, USA, Konstanz & Munich, Germany and Tokyo, Japan. For more information, please visit www.genedata.com.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
# # #
Read the full story at http://www.prweb.com/releases/Expressionist/transcriptomics/prweb3061464.htm.
Copyright©2009 Vocus, Inc.
All rights reserved